Celldex Therapeutics, Inc. (CLDX) News
Follow Celldex Therapeutics, Inc. (CLDX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: NASDAQ:CLDX plunge and anaphylaxis warning label
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares dropped after data showed barzolvolimab boosted efficacy and angioedema resolution by weeks 12—24 in a 24-week trial, but two probable Grade 4 anaphylaxis cases prompted co
REGULATION | Sep 28, 2026, 11:06 AM UTC
L
Celldex Therapeutics Is Maintained at Outperform by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 01:31 PM UTC
L
Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target
Leerink Partners maintained their Outperform rating on Celldex Therapeutics's stock with a price target of $88.00.The price target implies an upside of 162.6% from the Sep 22 close of $33.51.Key takeaways from the analys
EQUITY | Sep 23, 2026, 01:21 PM UTC
L
Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley
Ratings actions from Benzinga: GMT) Celldex Therapeutics Price Target Raised to $57.00/Share From $50.00 by Morgan StanleyRatings actions from Benzinga
NEWS | Sep 23, 2026, 11:46 AM UTC
M
Celldex shares slip after skin drug trial results
Celldex Therapeutics said its experimental drug significantly reduced disease activity in two late-stage trials in patients with a chronic skin condition, but shares fell nearly 15% as safety concerns weighed on the resu
EQUITY | Sep 22, 2026, 03:02 PM UTC
M
Celldex drug meets goals in two late-stage trials
Celldex Therapeutics said its experimental drug for a skin disease met the main and secondary goals in two late-stage trials.
EQUITY | Sep 22, 2026, 11:38 AM UTC
L
CLDX - Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
CLDX - Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
NEWS | Sep 22, 2026, 11:02 AM UTC
L
Celldex price target raised to $50 from $46 by Morgan Stanley
Morgan Stanley raised its price target on Celldex Therapeutics to $50.00 per share from $46.00. The stock is maintained at Overweight by Morgan Stanley, per Benzinga via TradingView News.
EQUITY | Sep 10, 2026, 05:38 PM UTC
L
CLDX to present at upcoming investor conference
CLDX plans to present at an upcoming investor conference.
EQUITY | Sep 08, 2026, 08:01 PM UTC
L
CLDX Celldex Therapeutics shares down 2.6% after scrapping development of skin disease drug
CLDX Celldex Therapeutics shares down 2.6% after scrapping development of skin disease drug
EQUITY | Jul 22, 2026, 01:34 PM UTC
L
CLDX Barzolvolimab Misses on PN; CSU Data Expected in September/October Remain the Big Focus @ Cantor
CLDX Barzolvolimab Misses on PN; CSU Data Expected in September/October Remain the Big Focus @ Cantor
EQUITY | Jul 22, 2026, 01:09 PM UTC
L
CLDX shares -5.3% premarket after saying its experimental drug barzolvolimab failed in a Phase 2 study in the skin condition prurigo nodular
CLDX shares -5.3% premarket after saying its experimental drug barzolvolimab failed in a Phase 2 study in the skin condition prurigo nodularis; is continuing to test the drug in a number of other indications, with data e
EQUITY | Jul 22, 2026, 12:35 PM UTC
L
CLDX Raise PT to $100 from $90 ahead of pivotal EMBARQ-CSU1/2 topline readout (n=1,939) expected in Q426 (GUGG estimate October) @ GUGG
CLDX Raise PT to $100 from $90 ahead of pivotal EMBARQ-CSU1/2 topline readout (n=1,939) expected in Q426 (GUGG estimate October) @ GUGG
EQUITY | Jul 20, 2026, 01:14 PM UTC
L
CLDX Celldex announces planned transition of Chief Financial Officer Celldex Therapeutics - celldx CFO sam Martin plans to retire in 2027
CLDX Celldex announces planned transition of Chief Financial Officer Celldex Therapeutics - celldx CFO sam Martin plans to retire in 2027 - Celldx begins search for new CFO; sam Martin to remain through March 2027
EQUITY | Jul 15, 2026, 08:01 PM UTC